Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US STOCKS-Wall St flat after retail sales, Nasdaq edges higher

Mon, 13th May 2013 16:41

* Core U.S. retail sales rise 0.5 percent in April

* Yum Brands falls as monthly Chinese sales drop

* Crude oil falls, pressuring energy companies

* Indexes: Dow down 0.2 pct, S&P up 0.1 pct, Nasdaq up 0.3pct

By Ryan Vlastelica

NEW YORK, May 13 (Reuters) - U.S. stocks were mostly flat onMonday as investors paused following a rally that took indexesto record highs, though a strong read on retail sales limiteddeclines and the Nasdaq ticked up on a rally in Netflix.

The S&P 500 has jumped more than 14 percent so far thisyear, a rally that has repeatedly taken it to record intradayand closing highs without sustained declines. While thelong-term trend is still viewed as positive, many analysts saidthe momentum could wane in the absence of positive catalysts.

Retail sales rose 0.1 percent in April, better than the 0.3percent drop that had been expected, and returning to growthfollowing a decline in March.

Excluding autos, gasoline and building materials, core salesrose 0.5 percent. Retail sales account for about 30 percent ofU.S. consumer spending.

"Recent data has been weak, so to see some sturdiness isimportant and needed in order for us to move materially higher,"said Mark Luschini, chief investment strategist at JanneyMontgomery Scott in Philadelphia. "But given the strength we'vehad over the past few weeks, it isn't surprising that trading isa bit indifferent today."

The S&P 500 managed its third straight weekly gainlast week, reaching a record high on Friday. The benchmark had a five-day streak of record closing highs before settling loweron Thursday.

The Dow Jones industrial average was down 24.04points, or 0.16 percent, at 15,094.45. The Standard & Poor's 500Index was up 1.41 points, or 0.09 percent, at 1,635.11.The Nasdaq Composite Index was up 8.40 points, or 0.24percent, at 3,444.99.

Netflix Inc jumped 4.2 percent to $226.81 as one ofthe biggest advancing stocks in the S&P 500, helping to keep theNasdaq in slightly positive territory.

Other data showed business inventories were unchanged inMarch for a second straight month versus expectations of 0.3percent rise, suggesting restocking could help second-quartereconomic growth.

Crude oil fell 0.7 percent to $95.39 per barrel,pressured by a drop to an eight-month low in demand in China.

Luschini, who helps oversee $58 billion in assets, said thedrop in oil and gasoline prices contributed to the strong readon retail sales, "so it is helpful to see those remain tame.

"However, if we dip below $90 a barrel, that will hurt theenergy sector and could be a signal of lower global growth."

Consol Energy fell 2 percent to $34.14 whileNational Oilwell Varco was off 1.4 percent at $67.27.

Yum Brands Inc fell 2.6 percent to $68.54. After themarket closed on Friday, the fast food chain operator posted asteep decline in Chinese April sales.

With 90 percent of the S&P 500 having reported, 67.2 percentof companies have topped earnings expectations, according toThomson Reuters data, an amount that is even with the averageover the past four quarters. Only 46.9 percent have beatenrevenue expectations, under the 52 percent average over the pastfour quarters.

Elan agreed to a $1 billion deal to buy 21percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline for itsrespiratory drugs. Theravance shares jumped 15 percent to$40.33.

U.S.-listed shares of Perion Network surged 12percent to $14.10 after the Israeli consumer Internet companyposted first-quarter earnings.

SoftBank Corp has told banks that their financingof Dish Network Corp's $25.5 billion rival offer forSprint Nextel Corp could hurt their chances of landing arole in a highly anticipated public offering of Chinesee-commerce giant Alibaba Group Holding Ltd, two sources familiarwith the situation said.

Sprint shares dipped 1.6 percent to $7.24 while Dish lost1.7 percent to $38.51.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.